FILTER
LATEST INTERVIEWS
Alberto Veneruso
MANAGING DIRECTOR, GEVEN FEBRUARY 2, 2017
Geven is expanding the customer base for its aircraft passenger seats and increasing manufacturing capacity to meet the growing demand.
Antonio de Palmas
PRESIDENT, BOEING
Boeing has long been a fundamental part of Italy’s aerospace industry.
Tay Kok Khiang
CHAIRMAN, A*STAR AEROSPACE PROGRAM AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
A*STAR Aerospace helps the Singapore aerospace industry to maintain a technological advantage through its Aerospace Research Consortium.
Eduardo Espinosa
COMMERCIAL MANAGER ANDEAN REGION, MARTIN ENGINEERING
Marin Engineering is developing techniques and technology to improve efficiency and safety.
Alberto Piñones
GENERAL OPERATIONS DIRECTOR, HITACHI
Hitachi explains its strategy for its Mexican automotive divisions.
Dr. Jan Hegner
CEO, DAIMLER BUSES MEXICO
Daimler Buses Mexico explains its plans to maintain its strong presence in the Mexican automotive market.
Richard Spencer
PRESIDENT & CEO, U3O8 CORP.
U3O8 is bringing an Uranium and Vanadium resource to production in Patagonia and is seeing good prospects to meet local demand.
Lim Yeow Khee
PRESIDENT, SINGAPORE INSTITUTE OF AEROSPACE ENGINEERS
The SIAE struggles to keep up with the fast growth of the aviation industry in South East Asia, which requires a vast number of well-trained engineers and technicians.
Suri Chetty
DIRECTOR, BUSINESS DEVELOPMENT, UNICHEM
Unichem are in partnership with Novvi to bring synthetic renewable and biodegradable hydrocarbon production to South Africa.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
